Prognostic markers in renal cell carcinoma

Purpose of review This article reviews recent reports on prognostic markers in renal cell carcinoma. Recent findings Inclusion in studies of larger cohorts of patients has yielded enhanced prognostic information from integrated pathological markers; the findings suggest that adjustment to the TNM (tumour–node–metastasis) system is warranted. A number of patient-related factors remain important prognostically, including performance status, C-reactive protein and thrombocytosis, but also immunological factors (e.g. expression of B7-H1 by renal cell carcinomas is associated with progression). Additional prognostic information may be derived from a range of molecular markers. Findings of gene array and methylation studies may yield independent prognostic information. Enhanced knowledge of signalling pathways has facilitated better understanding of underlying biology and prediction of response to treatment. Other genes involved in regulating hypoxia-inducible factor [e.g. genes encoding carbonic anhydrase-IX and PTEN (phosphatase and tensin homolog)] were reported to be prognostically important in renal cell carcinoma. Other markers independently predicted survival (e.g. thymidine-phosphorylase and survivin). Summary The potential of molecular markers suggested by clinical research is encouraging. Knowledge of various pathways will facilitate creation of systems of biomarkers that are predictive of individual response to therapy. Useful biomarkers may have potential as therapeutic targets.

[1]  A. Chkhotua,et al.  Loss of p27(Kip1) CDKI is a predictor of poor recurrence-free and cancer-specific survival in patients with renal cancer , 2007, International Urology and Nephrology.

[2]  J. Cheville,et al.  Tumor B 7-H 1 Is Associated with Poor Prognosis in Renal Cell Carcinoma Patients with Long-term Follow-up , 2006 .

[3]  J. Lam,et al.  Prognostic relevance of capsular involvement and collecting system invasion in stage I and II renal cell carcinoma , 2007, BJU international.

[4]  J. Köllermann,et al.  Expression parameters of the inhibitors of apoptosis cIAP1 and cIAP2 in renal cell carcinomas and their prognostic relevance. , 2007, International journal of cancer.

[5]  Y. Ko,et al.  MET Expression in Sporadic Renal Cell Carcinomas , 2006, Journal of Korean medical science.

[6]  Y. Furuya,et al.  Serum immunosuppressive acidic protein doubling time as a prognostic factor for recurrent renal cell carcinoma after nephrectomy. , 2006, Urology.

[7]  V. Bilim,et al.  Absence of Bcl-2 and Fas/CD95/APO-1 predicts the response to immunotherapy in metastatic renal cell carcinoma , 2006, British Journal of Cancer.

[8]  Robert Tibshirani,et al.  Gene Expression Profiling Predicts Survival in Conventional Renal Cell Carcinoma , 2005, PLoS medicine.

[9]  W. Linehan,et al.  Expression of Hypoxia Inducible Factor-1α and 2α in Genetically Distinct Early Renal Cortical Tumors , 2006 .

[10]  J. Cheville,et al.  Lower expression levels of the transforming growth factor beta receptor type II protein are associated with a less aggressive tumor phenotype and improved survival among patients with clear cell renal cell carcinoma. , 2007, Human pathology.

[11]  V. Ficarra,et al.  Proposal for reclassification of the TNM staging system in patients with locally advanced (pT3-4) renal cell carcinoma according to the cancer-related outcome. , 2007, European urology.

[12]  H. von der Maase,et al.  Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Yusuke Nakamura,et al.  Genome-wide gene expression profiles of clear cell renal cell carcinoma: identification of molecular targets for treatment of renal cell carcinoma. , 2006, International journal of oncology.

[14]  M. Mansukhani,et al.  Detection of carbonic anhydrase-9 gene expression in peripheral blood cells predicts risk of disease recurrence in patients with renal cortical tumors. , 2006, Urology.

[15]  K. Bensalah,et al.  Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease: prognostic indicators of disease-specific survival. , 2007, European urology.

[16]  J. Köllermann,et al.  Expression parameters of the inhibitors of apoptosis cIAP1 and cIAP2 in renal cell carcinomas and their prognostic relevance , 2006 .

[17]  K. Grankvist,et al.  Different isoform patterns for vascular endothelial growth factor between clear cell and papillary renal cell carcinoma , 2006, BJU international.

[18]  Ying Huang,et al.  Vascular Cell Adhesion Molecule 1 Predicts Cancer-Free Survival in Clear Cell Renal Carcinoma Patients , 2006, Clinical Cancer Research.

[19]  D. Gutmann,et al.  Promoter hypermethylation of the potential tumor suppressor DAL‐1/4.1B gene in renal clear cell carcinoma , 2006, International journal of cancer.

[20]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[21]  K. Grankvist,et al.  Hypoxia-Inducible Factor 1α Expression in Renal Cell Carcinoma Analyzed by Tissue Microarray , 2006 .

[22]  Holger Moch,et al.  The Heidelberg classification of renal cell tumours , 1997, The Journal of pathology.

[23]  K. Ito,et al.  Impact of thrombocytosis and C‐reactive protein elevation on the prognosis for patients with renal cell carcinoma , 2006, International journal of urology : official journal of the Japanese Urological Association.

[24]  B. Ljungberg,et al.  Adrenal metastasis in renal cell carcinoma: A recommendation for adjustment of the TNM staging system , 2005, Scandinavian journal of urology and nephrology.

[25]  U. Stenman,et al.  Expression of human chorionic gonadotropin beta-subunit type I genes predicts adverse outcome in renal cell carcinoma. , 2006, The Journal of molecular diagnostics : JMD.

[26]  J. Cheville,et al.  Extranodal extension in regional lymph nodes is associated with outcome in patients with renal cell carcinoma. , 2006, The Journal of urology.

[27]  K. Grankvist,et al.  Angiogenesis and other markers for prediction of survival in metastatic renal cell carcinoma , 2007, Scandinavian journal of urology and nephrology.

[28]  Roudebush Vamc,et al.  THE HEIDELBERG CLASSIFICATION OF RENAL CELL TUMOURS , 1997 .

[29]  Ximing J. Yang,et al.  Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma. , 2007, Cancer research.

[30]  K. Rock,et al.  Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. , 2006, The Lancet. Oncology.

[31]  S. Venz,et al.  Expression of annexin AI in conventional renal cell carcinoma (CRCC) correlates with tumour stage, Fuhrman grade, amount of eosinophilic cells and clinical outcome. , 2007, Histology and histopathology.

[32]  S. Hanash,et al.  Ubiquitin COOH-Terminal Hydrolase 1: A Biomarker of Renal Cell Carcinoma Associated with Enhanced Tumor Cell Proliferation and Migration[?Q1: Running head: UCHL1, a Biomarker of RCC. Short title OK?Q1] , 2007, Clinical Cancer Research.

[33]  M. Ashcroft,et al.  Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. , 2006, Cancer research.

[34]  J. Köllermann,et al.  Promoter Hypermethylation Profile of Kidney Cancer with New Proapoptotic p53 Target Genes and Clinical Implications , 2006, Clinical Cancer Research.

[35]  S. Byun,et al.  Expression of survivin in renal cell carcinomas: association with pathologic features and clinical outcome. , 2007, Urology.

[36]  A. Haitel,et al.  Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable , 2006, British Journal of Cancer.

[37]  W. Linehan,et al.  Expression of hypoxia inducible factor-1alpha and 2alpha in genetically distinct early renal cortical tumors. , 2006, The Journal of urology.

[38]  J. Cheville,et al.  The preoperative erythrocyte sedimentation rate is an independent prognostic factor in renal cell carcinoma , 2006, Cancer.

[39]  M. Brunelli,et al.  Prognostic role of the histologic subtypes of renal cell carcinoma after slide revision. , 2006, European urology.

[40]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[41]  K. Bensalah,et al.  Prognostic value of thrombocytosis in renal cell carcinoma. , 2006, The Journal of urology.

[42]  E. Bollito,et al.  Reassessing the current TNM lymph node staging for renal cell carcinoma. , 2006, European urology.

[43]  O. Tawfik,et al.  Prognostic significance of CD44, platelet-derived growth factor receptor alpha, and cyclooxygenase 2 expression in renal cell carcinoma. , 2009, Archives of pathology & laboratory medicine.

[44]  Bin Tean Teh,et al.  Two Distinct Types of Blood Vessels in Clear Cell Renal Cell Carcinoma Have Contrasting Prognostic Implications , 2007, Clinical Cancer Research.

[45]  I. H. Chang,et al.  Significance of macroscopic tumor necrosis as a prognostic indicator for renal cell carcinoma. , 2006, The Journal of urology.

[46]  F. Kai,et al.  High levels of thymidine phosphorylase as an independent prognostic factor in renal cell carcinoma. , 2006, Japanese journal of clinical oncology.

[47]  K. Grankvist,et al.  Endoglin (CD105) expression in human renal cell carcinoma , 2006, BJU international.

[48]  K. Grankvist,et al.  Different vascular endothelial growth factor (VEGF), VEGF‐receptor 1 and ‐2 mRNA expression profiles between clear cell and papillary renal cell carcinoma , 2006, BJU international.

[49]  R. Motzer,et al.  Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma , 2005, Cancer.

[50]  R. Motzer,et al.  Targeting von Hippel-Lindau Pathway in Renal Cell Carcinoma , 2006, Clinical Cancer Research.

[51]  J. Cheville,et al.  High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma , 2006, Cancer.

[52]  J. Cheville,et al.  Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. , 2006, Cancer research.

[53]  J. Cheville,et al.  Reclassification of patients with pT3 and pT4 renal cell carcinoma improves prognostic accuracy , 2005, Cancer.

[54]  H. Akaza,et al.  Expression profile of N-cadherin differs from other classical cadherins as a prognostic marker in renal cell carcinoma. , 2006, Oncology reports.

[55]  D. Yılmazer,et al.  A comparison of the vascular density of VEGF expression with microvascular density determined with CD34 and CD31 staining and conventional prognostic markers in renal cell carcinoma , 2006, International Urology and Nephrology.